ベータラクタム及びベータラクタマーゼ阻害剤の世界市場:薬物クラス別、疾患別、投与経路別...市場調査レポートについてご紹介

【英文タイトル】Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.3.1. List of Key Players Profiled In The Report

1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1.1. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Top Winning Strategies

3.3.1. Top Player Positioning, 2018

3.4. Porter’S Five Forces Analysis
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Increased Consumption In Low And Middle-Income Countries (Lmics)
3.5.1.2. Rise In Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches For New Beta-Lactam And Beta-Lactamase Inhibitors For Treating Bacterial Infections

3.5.2. Restraints

3.5.2.1. Development of Beta-Lactam Resistance
3.5.2.2. Longer Approval Time By The Regulatory Bodies

3.5.3. Opportunity

3.5.3.1. Discovery of Advanced Prospect Molecules And Novel Combination Therapies To Treat Antibiotic-Resistant Microbial Infections

3.6. Antimicrobial Resistance And Countermeasure Trends

3.6.1. Countermeasure Trends

Chapter 4: Beta-Lactam And Beta Lactamase Inhibitors Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Penicillin

4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country

4.3. Cephalosporin

4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country

4.4. Carbapenem

4.4.1. Key Market Trends And Growth Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis, By Country

4.5. Monobactam

4.5.1. Key Market Trends And Growth Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis, By Country

4.6. Combination

4.6.1. Key Market Trends And Growth Opportunities
4.6.2. Market Size And Forecast, By Type

4.6.2.1. Penicillin/Beta Lactamase Inhibitors

4.6.2.1.1. Market Size And Forecast

4.6.2.2. Cephalosporins/Beta Lactamase Inhibitors

4.6.2.2.1. Market Size And Forecast

4.6.2.3. Carbapenems/Beta Lactamase Inhibitors

4.6.2.3.1. Market Size And Forecast

4.6.3. Market Size And Forecast, By Region
4.6.4. Market Analysis, By Country

Chapter 5: Beta-Lactam And Beta Lactamase Inhibitors Market, By Disease

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Urinary Tract Infection (Excluding Cuti)

5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country

5.3. Respiratory Infection

5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country

5.4. Skin Infection

5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country

5.5. Complicated Urinary Tract Infection (Cuti)

5.5.1. Market Size And Forecast, By Region
5.5.2. Market Analysis, By Country
5.5.3. Number of Patients, By Country

5.6. Complicated Intra-Abdominal Infections (Ciai)

5.6.1. Market Size And Forecast, By Region
5.6.2. Market Analysis, By Country
5.6.3. Number of Patients, By Country

5.7. Nosocomial Pneumonia

5.7.1. Market Size And Forecast, By Type

5.7.1.1. Hospital Acquired Pneumonia

5.7.1.1.1. Market Size And Forecast

5.7.1.2. Ventilator Associated Pneumonia

5.7.1.2.1. Market Size And Forecast

5.7.1.3. Other Nosocomial Pneumonia

5.7.1.3.1. Market Size And Forecast

5.7.2. Market Size And Forecast, By Region
5.7.3. Market Analysis, By Country
5.7.4. Number of Patients, By Country

5.8. Blood Stream Infection

5.8.1. Market Size And Forecast, By Region
5.8.2. Market Analysis, By Country
5.8.3. Number of Patients, By Country

5.9. Other Diseases

5.9.1. Market Size And Forecast, By Region
5.9.2. Market Analysis, By Country

Chapter 6: Beta-Lactam And Beta Lactamase Inhibitors Market, By Route of Administration

6.1. Overview

6.1.1. Market Size And Forecast

6.2. Oral

6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country

6.3. Intravenous

6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country

6.4. Others

6.4.1. Market Size And Forecast, By Region
6.4.2. Market Analysis, By Country

Chapter 7: Beta-Lactam And Beta-Lactamase Inhibitors Market, By Region

7.1. Overview

7.1.1. Market Size And Forecast

7.2. North America

7.2.1. Key Market Trends And Opportunities
7.2.2. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.2.2.1. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.2. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.3. U.S. Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.4. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.5. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.6. Canada Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.2.2.7. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.2.2.8. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.2.2.9. Mexico Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.2.3. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.2.4. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.2.5. North America Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

7.3. Europe

7.3.1. Key Market Trends And Opportunities
7.3.2. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.3.2.1. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.2. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.3. Germany Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.4. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.5. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.6. France Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.7. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.8. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.9. Spain Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.10. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.11. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.12. Italy Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.13. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.14. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.15. Uk Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.3.2.16. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.3.2.17. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.3.2.18. Rest of Europe Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.3.3. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.3.4. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.3.5. Europe Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

7.4. Asia-Pacific

7.4.1. Key Market Trends And Opportunities
7.4.2. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.4.2.1. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.2. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.3. Japan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.4. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.5. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.6. India Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.7. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.8. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.9. China Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.10. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.11. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.12. South Korea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.13. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.14. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.15. Indonesia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.16. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.17. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.18. Thailand Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.19. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.20. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.21. Vietnam Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.22. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.23. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.24. Taiwan Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.4.2.25. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.4.2.26. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.4.2.27. Rest of Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.4.3. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.4.4. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.4.5. Asia-Pacific Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

7.5. Lamea

7.5.1. Key Market Trends And Opportunities
7.5.2. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Country

7.5.2.1. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.2. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.3. Brazil Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.4. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.5. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.6. Saudi Arabia Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.7. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.8. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.9. South Africa Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration
7.5.2.10. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Drug Class
7.5.2.11. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Disease
7.5.2.12. Rest of Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market By Route of Administration

7.5.3. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Drug Class
7.5.4. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Disease
7.5.5. Lamea Beta-Lactam And Beta-Lactamase Inhibitors Market, By Route of Administration

Chapter 8: Company Profiles

8.1. Abbott Laboratories

8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance

8.2. Allergan Plc.

8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments

8.3. F. Hoffmann-La Roche Ltd.

8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance

8.4. Glaxosmithkline Plc

8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance

8.5. Merck & Co. Inc.

8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments

8.6. Mylan N.V.

8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments

8.7. Novartis International Ag (Sandoz)

8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance

8.8. Pfizer Inc.

8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments

8.9. Sanofi

8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance

8.10. Teva Pharmaceutical Industries Ltd.

8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance


【レポート販売概要】

■ タイトル:ベータラクタム及びベータラクタマーゼ阻害剤の世界市場:薬物クラス別、疾患別、投与経路別
■ 英文:Beta-lactam and Beta-lactamase Inhibitors Market by Drug Class (Penicillin, Cephalosporin, Carbapenem, Monobactam, and Combination), Disease (Urinary Tract Infection, Respiratory Infection, Skin Infection, Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Nosocomial Pneumonia, Blood Stream Infection, and Other Diseases), and Route of Administration (Oral, Intravenous, and Other Route of Administrations): Global Opportunity Analysis and Industry Forecast, 2019–2028
■ 発行日:2019年8月
■ 調査会社:Allied Market Research
■ 商品コード:AMR9NV046
■ 調査対象地域:グローバル
  • 米国の原子力産業分析:Analyzing the Nuclear Power Industry in the US
    The United States is the world's largest supplier of commercial nuclear power. In recent years, there has been a renewed interest in nuclear power in the US. This has been facilitated in part by the federal government with the Nuclear Power 2010 Program, which coordinates efforts for building new nuclear power plants, and the Energy Policy Act which makes provisions for nuclear and oil industries. …
  • 建設おもちゃの世界市場2019-2023
    About this market The increasing popularity of toys as gifts, especially during festivals and occasions, will drive the construction toys market growth in the forthcoming years. The demand for toys including construction toys is increasing among people, as they offer various types of gifts such as toys to children during festivals and birthdays. Therefore, vendors in the market are offering produc …
  • 医療レポート:Hepatitis C Virus-疫学予測(~2022)
    EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Summary Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV is an escalating public health problem and burdens an estimated 3% of the world’s population (Trinks et al., 2012). Unlike other acute viral infections that have a rapid onset, HCV infections often persist for decades (CDC, 2013; T …
  • 世界の無人航空機市場
    In today’s context UAV’s play an important role in varied missions such as military attacks, border surveillance, mapping, surveying, weather determination and regional law enforcements. This technology has grown at a rapid pace and production companies present across the globe, as the country want to showcase their military strength in order to wade off potential attacks. Civilian usage of UAV op …
  • サードパーティーロジスティクス(3PL)の世界市場:輸送形態別(道路、鉄道、水路、空路)、最終用途別(製造、小売、ヘルスケア、自動車)、地域別予測
    Global Third-Party Logistics (3PL) Market to reach USD XXX billion by 2025. Global Third-Party Logistics (3PL) Market valued approximately USD XXX billion in 2016 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2017-2025. Variation in transportation capabilities and increased shipping demand have enabled service providers to enhance their supply chain ac …
  • エンタープライズリソースプランニング(ERP)ソフトウェアの世界市場2019-2023
    About this market The increased operational efficiency using ERPs will trigger the market during the forecast period. ERP software allows the linking of various modules with a single system for accessing data in real-time. In addition, ERP software also helps in lowering operating costs, enabling the strategic planning of core operations, and facilitating easy daily routine operations. Furthermore …
  • 双極性障害市場:現在・未来プレイヤー
    Bipolar Disorder - Current and Future Players Summary GlobalData has released its pharma report, “Bipolar Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Bipolar Disorder Market. The report identifies and analyses the key companies shaping and driving the global Bipolar Disorder market. Th …
  • 複合イベント処理(CEP)の世界市場予測(~2020)
    MarketsandMarkets forecast the Complex Event Processing market size to grow from USD 1.28 Billion in 2015 to USD 4.95 Billion by 2020, at a compound annual growth rate (CAGR) of 31.1%. The adoption of device based computing and potential growth in demand for enterprise data worldwide are the main drivers of the CEP market. Presently, on-premise based deployment of CEP has the larger share than the …
  • ニードルフリーIVコネクターの世界市場2018-2022
    About Needle-Free IV Connectors Needle-free IV connectors are used to connect administration sets, syringes, and IV catheters. Technavio’s analysts forecast the global needle-free IV connectors market to grow at a CAGR of 9.56% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth prospects of the global needle-free IV connectors market for 2018- …
  • 金融部門におけるバイオメトリクス(生体認証)の世界市場2016-2020
    About Biometrics Market in BSFI SectorSecurity of data and financial assets have been a key concern for banks as well as for customers. Numeric keypads, keys, and identity badges were widely used to prevent unauthorized access to data and premises. With technological advancements, two-factor authentication was introduced, where individuals could gain access to secure premises after they are authen …
  • 世界のシロップ及びスプレッド市場動向:企業M&A(2014年5月)
    Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global syrups & spreads market during May 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global syrups & spreads market throughout the month. Additionally, the report provides an overview of al …
  • 電気集塵器の世界市場:乾式電気集塵装置、湿式電気集塵装置
    The global ESP systems market is projected to grow at a CAGR of 5.7% from 2014 to 2019. Although Asia-Pacific holds the largest share of the global market, the African market for ESP systems is expected to grow at the highest CAGR during the forecast period. The rising industrial development and regulations to control industrial emissions are the driving factors for this regional market. On the gl …
  • 家庭/自己診断検査市場:戦略分析
    This new 175-page report from VPGMarketResearch.com provides analysis of the major home/self testing market segments, including diabetes (strips and meters), pregnancy, ovulation, and occult blood.  The report presents trends, dynamics, size, growth, regulatory requirements, technologies, and competitive profiles.RationaleThe growing economic pressures on hospitals, coupled with advances …
  • サーマル(熱攻法)石油増進回収法(EOR)の世界市場2016-2026
    Visiongain’s fresh industry update indicates that spending on thermal EOR projects will total $17.8bn and incremental oil production will total 2.27 MMbpd in 2016. The report will answer questions such as: • How is the thermal EOR market evolving? • What are the prospects for each of the thermal EOR submarkets over the next decade? • Who are the main companies in the thermal EOR market and what ar …
  • アメリカの再生医療市場2016-2020
    Regenerative medicine deals with the process of using therapeutically-induced or laboratory grown human tissue to treat diseased or injured human cells, tissues, or organs. It is an emerging field of treatment that helps in producing new cells to substitute malfunctioning or injured cells as a vehicle to treat disease and injury. The regenerative medicine market can be characterized into three maj …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。